Hennessy, Bryan T
Breathnach, Oscar S
Morris, Patrick G
MetadataShow full item record
JournalIrish journal of medical science
AbstractBackground: Clinical trials are often considered the gold standard in cancer care. However, patients face barriers in trial participation including distances to cancer centres and personal costs including changing employment status, cost of medications, inpatient admissions, and parking tariffs. Aim: Our aim was to compare the distances patients travelled for clinical trials compared to those receiving standard systemic anticancer therapy (SACT). We also investigated the additional costs associated with this. Methods: This was a retrospective review of electronic patient medical records. The distance from the patients' home address to Beaumont was calculated as a one-way journey in kilometres. Patients attending for clinical trials were compared to those receiving standard of care SACT. Results: A total of 271 patients receiving standard SACT over a 5-day period and 111 patients enrolled on 24 clinical trials were included. The median one-way distance travelled by patients enrolled in clinical trials was 41.4 km, compared to 14 km in those patients' receiving standard of care SACT. The median estimated cost was €13 vs €4.20 for those enrolled on clinical trials compared to those receiving standard of care treatment, respectively. Conclusion: Patients enrolled on clinical trials often travel more than twice as far to receive their anti-cancer treatment compared to those receiving standard of care SACT and incur an increased cost of travel expenses.
- At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.
- Authors: Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ
- Issue date: 2018 Oct
- Thirty-day mortality after systemic anticancer treatment as a real-world, quality-of-care indicator: the Northland experience.
- Authors: Ang E, Newton LV
- Issue date: 2018 Apr
- Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.
- Authors: Hofmarcher T, Lindgren P, Wilking N
- Issue date: 2022 Dec
- Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review.
- Authors: Geyer T, Le NS, Groissenberger I, Jutz F, Tschurlovich L, Kreye G
- Issue date: 2023 Oct
- Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent.
- Authors: Ribi K, Kalbermatten N, Eicher M, Strasser F
- Issue date: 2022 Jun